Browse Products By Molecule:

This web search service is supported by Google Inc.

Bulk Recombinant Proteins --->Lymphocyte-activation gene 3 (LAG-3)

Lymphocyte-activation gene 3 (LAG-3)  


The clinical success of several anti-PD1 and anti-CTLA4 antibodies has boosted the research of other immune checkpoint proteins. The lymphocyte-activation gene 3 (LAG-3), is of particular interest to researchers because it functions differently from the canonical negative checkpoint regulators such as PD1 and CTLA4.

LAG-3 is expressed on cell membranes of natural killer cells (NK), B cells, tumor-infiltrating lymphocytes (TIL), T cells, and dendritic cells (DC), and it appears to play complicated roles in the immune pathway. The binding between soluble LAG-3 (sLAG-3) and MHCII molecules promotes the maturation of dendritic cells, while the interaction between MHCII and LAG-3 on membrane leads to the negative regulation of T-cell activity.

lag3-Launched.jpg

Several therapeutic agents have been developed to target the LAG-3 pathway. IMP321, a sLAG-3-Fc fusion protein developed by Prima Biomed, is one of the leading drugs that currently being investigated in a phase II clinical trial. IMP321 augments immune response against cancer cells through two distinct mechanisms. It binds with MHCII molecules on the immature dendritic cells to enhance tumor antigen presentation. At the same time, it also blocks the MHCII molecule to bind with LAG-3-expressing CD8+ T-cells, and by so doing prevents the T-cells from being negatively regulated. Other investigative drugs, such as Bristol-Myers Squibb's anti-LAG-3 antibody BMS-986016, directly bind with LAG-3 expressed on the T-cells and block the LAG-3-MHCII interaction. As a result, the T-cells can be activated to boost immune response.

ACROBiosystems provides a comprehensive panel of LAG-3 proteins, including Cynomolgus LAG-3, Mouse IgG2a Fc Tag (Cat. No. LA3-C52A0), Cynomolgus LAG-3, Fc Tag (Cat. No. LA3-C5252), and Human LAG-3, Fc Tag (Cat. No. LA3-H5255).

LAG-3 Product List

Cat. No. Species Product Description Structure Purity Features
LA3-C52A0 Cynomolgus Cynomolgus LAG-3 / CD223, Mouse IgG2a Fc Tag
LA3-C5252 Cynomolgus Cynomolgus LAG-3, Fc Tag
LA3-H5255 Human Human LAG-3 / CD223, Fc Tag
LA3-H5222 Human Human LAG-3 / CD223
LA3-H52Aa Human Human LAG-3 / CD223, Mouse IgG2a Fc Tag LA3-H52Aa
LA3-M52H5 Mouse Mouse LAG-3 / CD223
LA3-M52H5.jpg
LA3-R52H5 Rat Rat LAG-3 / CD223

Product Highlight

The comparison between ACRO LAG-3 and Company R LAG-3 by SEC-HPLC and ELISA

la3-h5255-elisa

Fig. 1 The purity of ACROBiosystems Human LAG-3, Fc Tag (Cat. No. LA3-H5255) is determined to be greater than 99%, while the purity of a comparable product from company R is determined to be greater than 87%.

CD8-H82E7

Fig. 2 ACROBiosystems Human LAG-3, Fc Tag (Cat. No. LA3-H5255) demonstrates higher binding affinity with an unpublished Anti-LAG3 MAb, compared with a similar product from company R.

The FACS analysis of ACRO Human LAG-3, Fc Tag against Daudi cells

CD8-H82E7

Fig. 3 The FACS result shows that ACRO's Human LAG-3, Fc Tag (Cat. No. LA3-H5255, marked in red) can bind with MHCII expressing Daudi cells.